Investors & Media


May 25, 2023

NGM Bio to Participate in Upcoming Investor Conferences

May 8, 2023

NGM Bio Announces Presentation of Data from Phase 2 Investigator-Sponsored Trial of Aldafermin for the Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) and Bile Acid Malabsorption (BAM) at Digestive Disease Week 2023

May 4, 2023

NGM Bio Reports First Quarter 2023 Financial Results and Provides Business Highlights, Including Topline ALPINE 4 Data

March 1, 2023

NGM Bio to Participate in the Cowen 43rd Annual Health Care Conference

February 28, 2023

NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results

January 12, 2023

NGM Bio to Participate in the B. Riley Securities 3rd Annual Oncology Conference

January 9, 2023

NGM Bio Outlines Corporate Strategy and Provides Guidance on Key Priorities

Contact Information

investor relations

media relations